title: Breakthrough in ER+ breast cancer.  Specific gene's shutdown is detectable in blood; indicates cancer cell vulnerability, thus enabling earlier treatment.
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000517:prevention & control; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004965:Estrogen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D019254:Genes, bcl-2 / Q000187:drug effects / Q000235:genetics*; D005819:Genetic Markers; D006801:Humans; D011960:Receptors, Estrogen / Q000187:drug effects / Q000235:genetics*; D055502:Secondary Prevention; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D005819:Genetic Markers; D011960:Receptors, Estrogen; D013629:Tamoxifen